Patient info Open main menu

Lupaxis 100 mg prolonged-release tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Controlled drug (Schedule 2) No longer supplied Details

Medicine strength:
100 mg
Contains active substance:
ATC code:
Similar medicines:

Patient leaflet - Lupaxis 100 mg prolonged-release tablets

1. What LUPAXIS is and what it is used for

The full name of your medicine is ‘LUPAXIS Prolonged-release Tablets’

It is referred to as ‘LUPAXIS’ in this leaflet.

LUPAXIS contains the active substance tapentadol. Tapentadol is a pain medication which belongs to the class of strong opioids. Tapentadol is used for the treatment of:

  • severe chronic pain in adults that can only be adequately

    managed with an opioid.

  • severe chronic pain in children above 6 years and

    adolescents that can only be adequately managed with an opioid.

2. What you need to know before you take LUPAXIS

Do not take LUPAXIS

  • if you are allergic to tapentadol or any of the other

    ingredients of this medicine (listed in section 6)

  • if you have asthma or if your breathing is dangerously slow

    or shallow (respiratory depression, hypercapnia)

  • If you have paralysis of the gut
  • if you have acute poisoning with alcohol, sleeping pills,

    pain relievers or other psychotropic medicines (medicines that affect mood and emotions) (see ‘Other medicines and LUPAXIS ’)

Warnings and precautions

Talk to your doctor or pharmacist before taking LUPAXIS if you:

  • have slow or shallow breathing
  • suffer from increased pressure in the brain or disturbed

    consciousness up to coma

  • have had a head injury or brain tumours
  • suffer from liver or kidney disease (see ‘How to take

    LUPAXIS’)

  • suffer from a pancreatic or biliary tract disease including

    pancreatitis

  • are taking medicines referred to as mixed opioid agonist/

    antagonists (e.g. pentazocine, nalbuphine) or partial mu-opioid agonists (e.g. buprenorphine)

  • have a tendency towards epilepsy or fits or if you are

    taking other medicines known to increase the risk of seizures because the risk of a fit may increase

  • are going to have an operation, or have just had an

    operation, please tell the doctor at the hospital that you are taking these tablets. Your doctor may adjust your treatment. These tablets should not be used for short-term pain after an operation owing to the increased risk of dependence and breathlessness.

Tolerance, dependence and addiction

This medicine contains tapentadol, which is an opioid. It can cause dependence and/or addiction.

This medicine contains tapentadol which is an opioid medicine. Repeated use of opioid may result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of LUPAXIS can also lead to dependence, abuse and addiction which may result in life-threatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use.

Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it.

The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to LUPAXIS if:

  • you or anyone in your family have ever abused or been

    dependent on alcohol, prescription medicines or illegal drugs (“addiction”).

  • you are a smoker.
  • you have ever had problems with your mood (depression,

    anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses.

If you notice any of the following signs whilst taking LUPAXIS, it could be a sign that you have become dependent or addicted:

  • You need to take the medicine for longer than advised by

    your doctor.

  • You need to take more than the recommended dose.
  • You might feel that you need to carry on taking your

    medicine, even when it doesn’t help to relieve your pain.

  • You are using the medicine for reasons other than

    prescribed, for instance, ‘to stay calm’ or ‘help you sleep’

  • You have made repeated, unsuccessful attempts to quit or

    control the use of the medicine.

  • When you stop taking the medicine you feel unwell,

    and you feel better once taking the medicine again (‘withdrawal effects’).

If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking LUPAXIS).

Children and adolescents

Children and adolescents with obesity should be monitored closely and the recommended maximum dose should not be exceeded.

Do not give this medicine to children below the age of 6 years.

Sleep-related breathing disorders

LUPAXIS can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.

Other medicines and LUPAXIS

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor will tell you which medicines are safe to take with Tapentadol.

  • The risk of side effects increases if you are taking

    medicines which may cause convulsions (fits), such as certain antidepressants or antipsychotics. The risk of having a fit may increase if you take Tapentadol at the same time. Your doctor will tell you whether Tapentadol is suitable for you.

  • Concomitant use of LUPAXIS and sedative medicines such

    as benzodiazepines or related drugs (certain sleeping pills

    or tranquillisers (e.g. barbiturates) or pain relievers such as opioids, morphine and codeine (also as cough medicine), antipsychotics, H1-antihistamines, alcohol, increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma, and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe LUPAXIS together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. The concomitant use of opioids and drugs used to treat epilepsy, nerve pain or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and may be life-threatening. Please tell your doctor if you are taking gabapentin or pregabalin or any sedative medicines, and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.

    • If you are taking a type of medicine that affects serotonin levels (e.g. certain medicines to treat depression), speak to your doctor before taking LUPAXIS as there have been cases of “serotonin syndrome”. Serotonin syndrome is a rare, but life-threatening condition. The signs include involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension and body temperature above 38 oC. Your doctor can advise you on this
    • Taking LUPAXIS together with other types of medicines referred to as mixed mu-opioid agonist/antagonists (e.g. pentazocine, nalbuphine) or partial mu-opioid agonists (e.g., buprenorphine) has not been studied. It is possible that LUPAXIS will not work as well if given together with one of these medicines. Tell your doctor in case you are currently treated with one of these medicines.
    • Taking LUPAXIS together with strong inhibitors or inducers

      (e.g. rifampicin, phenobarbital, St John’s Wort) of certain enzymes that are necessary to eliminate LUPAXIS from your body, may influence how well tapentadol works or may cause side effects, especially when this other medication is started or stopped. Please keep your doctor informed about all medicines you are taking.

    • LUPAXIS should not be taken together with monoamine oxidase inhibitors (certain medicines for the treatment of depression). Tell your doctor if you are taking MAO inhibitors or have taken these during the last 14 days. If you use LUPAXIS together with the below medicines that have anticholinergic effects the risk of side effects may be increased:
    • medicines to treat depression.
    • medicines used to treat allergies, travel sickness or nausea

      (antihistamines or antiemetics).

    • medicines to treat psychiatric disorders (antipsychotics or neuroleptics);
    • muscle relaxants.
    • medicines to treat Parkinson’s disease.

LUPAXIS with food, drink and alcohol

Do not drink alcohol whilst you are taking LUPAXIS, because some side effects such as drowsiness may be increased. Food does not influence the effect of this medicine.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Do not take this tablets:

  • if you are pregnant, unless your doctor has instructed you to do so, if used over prolonged periods during pregnancy, LUPAXIS may lead to withdrawal symptoms in the newborn baby, which might be life-threatening for the newborn if not recognized and treated by a doctor
  • during childbirth, because it could lead to dangerously slow or shallow breathing (respiratory depression) in the newborn
  • during breast-feeding, because tapentadol may be excreted in the breast milk

Driving and using machines

LUPAXIS may cause drowsiness, dizziness and blurred vision and may impair your reactions. This may especially happen when you start taking LUPAXIS , when your doctor changes your dosage or when you drink alcohol or take tranquilizers. Please ask your doctor whether it is permitted to drive a car or use machines.

The medicine can affect your ability to drive.

  • Do not drive while taking this medicine until you know how this medicine affects you.
  • It may be an offence to drive if your ability to drive safely is affected.

There is further information for patients who are intending to drive in Great Britain - go to https://www.gov.uk/drug-driving-law.

3. How to take LUPAXIS

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using LUPAXIS, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also“If you stop taking LUPAXIS” below).

Your doctor will adjust the dose according to the intensity of your pain and your individual pain sensitivity. In general, the lowest pain-relieving dose should be taken.

Adults

The usual dose is 1 tablet every 12 hours.

Total daily doses of Tapentadol greater than 500 mg tapentadol are not recommended.

Your doctor may prescribe a different, more appropriate dose or interval of dosing ,schedule if this is necessary for you. If you feel that the effect of these tablets is too strong or too weak, talk to your doctor or pharmacist.

Elderly patients

In elderly patients (above 65 years) usually no dose adjustment is necessary. However, the excretion of tapentadol may be delayed in some patients of this age group. If this applies to you, your doctor may recommend a different dosage regimen. Liver or kidney disease (insufficiency)

Patients with severe liver problems should not take these tablets. If you have moderate problems, your doctor will recommend a different dosage regimen. In case of mild liver problems, a dosage adjustment is not required.

Patients with severe kidney problems should not take these tablets. In case of mild or moderate kidney problems, a dosage adjustment is not required.

Use in children and adolescents

The dose of LUPAXIS for children and adolescents aged 6 years to less than 18 years is dependent on age and body weight. The correct dose will be determined by your doctor. A total dose of 500 mg per day, i.e. 250 mg given every 12 hours should not be exceeded.

Children and adolescents with kidney or liver problems should not take these tablets.

LUPAXIS is not suitable for children below the age of 6 years. How should you take LUPAXIS

LUPAXIS is for oral use.

Always swallow the tablets whole, with sufficient liquid. Don’t chew it, break it or crush it – this could lead to overdosing, because the drug will be released into your body too quickly. You may take the tablets on an empty stomach or with meals. The empty shell of the tablet may not be digested completely and thus be seen in stool. This should not worry you, since the medicine (active substance) of the tablet has already been absorbed in your body and what you see is just the empty shell.

How long should you take LUPAXIS

Do not take the tablets for longer than your doctor has told you.

If you take more LUPAXIS than you should

After taking very high doses, the following may be experienced

  • pin-point pupils,
  • vomiting,
  • drop in blood pressure,
  • fast heart beat,
  • collapse,
  • disturbed consciousness or coma (deep unconsciousness),
  • epileptic fits.
  • dangerously slow or shallow breathing or stopping

    breathing which may lead to death.

If this happens a doctor should be called immediately. If you forget to take LUPAXIS

If you forget to take the tablets, your pain is likely to return. Do not take a double dose to make up for a forgotten dose; simply continue taking the tablets as before.

If you stop taking LUPAXIS

If you interrupt or stop treatment too soon, your pain is likely to return. If you wish to stop treatment, please tell your doctor first before stopping treatment.

Generally, there will be no after-effects when treatment is stopped. However, on uncommon occasions, people who have been taking the tablets for some time may feel unwell if they abruptly stop taking them.

Symptoms may be:

  • restlessness, watery eyes, runny nose, yawning, sweating,

    chills, muscle pain and dilated pupils,

  • irritability, anxiety, backache, joint pain, weakness,

    abdominal cramps, difficulty in sleeping, nausea, loss of appetite, vomiting, diarrhoea, and increases in blood pressure, breathing or heart rate.

If you experience any of these complaints after stopping treatment, please contact your doctor.

You should not suddenly stop taking this medicine unless your doctor tells you to. If your doctor wants you to stop taking your tablets, he/she will tell you how to do this, this may include a gradual reduction of the dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. No additional side effects were observed in children and adolescents compared to adults.

Important side effects or symptoms to look out for and what to do if you are affected:

This medicine may cause allergic reactions. Symptoms may be wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching, especially those covering your whole body.

Another serious side effect is a condition where you breathe more slowly or weakly than expected. It mostly occurs in elderly and weak patients.

If you are affected by these important side effects contact a doctor immediately.

Other side effects that may occur:

Very common (may affect more than 1 in 10 people)

  • nausea,
  • constipation.
  • dizziness,
  • drowsiness,
  • headache.

Common (may affect up to 1 in 10 people)

  • decreased appetite,
  • anxiety,
  • depressed mood,
  • sleep problem,
  • nervousness,
  • restlessness,
  • disturbance in attention,
  • trembling,
  • muscle twitches,
  • flushing,
  • shortness of breath,
  • vomiting,
  • diarrhoea,
  • indigestion,
  • itching,
  • increased sweating,
  • rash,
  • feeling of weakness,
  • fatigue,
  • feeling of body temperature change,
  • mucosal dryness,
  • accumulation of water in the tissue (oedema).

Uncommon (may affect up to 1 in 100 people)

  • allergic reaction to medicines (including swelling beneath

    the skin, hives, and in severe cases difficulty breathing, a fall in blood pressure, collapse, or shock),

  • weight loss,
  • disorientation,
  • confusion,
  • excitability (agitation),
  • perception disturbances,
  • abnormal dreams,
  • euphoric mood,
  • depressed level of consciousness,
  • memory impairment,
  • mental impairment,
  • fainting,
  • sedation,
  • balance disorder,
  • difficulty in speaking,
  • numbness,
  • abnormal sensations of the skin (e.g. tingling, prickling),
  • abnormal vision,
  • faster heartbeat,
  • slower heartbeat,
  • palpitations,
  • decreased blood pressure,
  • abdominal discomfort,
  • hives,
  • delay in passing urine,
  • frequent urination,
  • sexual dysfunction,
  • drug withdrawal syndrome (see ‘If you stop taking

    Tapentadol),

  • feeling abnormal, irritability.

Rare (may affect up to 1 in 1,000 people)

  • drug dependence,
  • thinking abnormal,
  • epileptic fits,
  • near fainting,
  • coordination abnormal,
  • dangerously slow or shallow breathing (respiratory

    depression),

  • impaired gastric emptying
  • feeling drunk ,
  • feeling of relaxation.

Not known (frequency cannot be estimated from the available data)

  • delirium

In general, the likelihood of having suicidal thoughts and behaviour is increased in patients suffering from chronic pain. In addition, certain medicines for the treatment of

depression (which have an impact on the neurotransmitter system in the brain) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, data from human use of tapentadol do not provide evidence for an increased risk.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side affects you can help provide more information on the safety of this medicine.

5. How to store LUPAXIS

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What LUPAXIS contains

  • The active substance is tapentadol.

    LUPAXIS 25 mg prolonged-release tablets

    Each prolonged-release tablet contains 38.28 mg of Tapentadol phosphate equivalent to 25 mg tapentadol

    LUPAXIS 50 mg prolonged-release tablets

    Each prolonged-release tablet contains 76.57 mg of Tapentadol phosphate equivalent to 50 mg tapentadol

    LUPAXIS 100 mg prolonged-release tablets

    Each prolonged-release tablet contains 153.13 mg of Tapentadol phosphate equivalent to 100 mg tapentadol

    LUPAXIS 150 mg prolonged-release tablets

    Each prolonged-release tablet contains 229.70 mg of Tapentadol phosphate equivalent to 150 mg tapentadol

    LUPAXIS 200 mg prolonged-release tablets Each prolonged-release tablet contains 306.27 mg of Tapentadol phosphate equivalent to 200 mg tapentadol

    LUPAXIS 250 mg prolonged-release tablets Each prolonged-release tablet contains 382.84 mg of Tapentadol phosphate equivalent to 250 mg tapentadol

  • The other ingredients are:

    Tablet core:

    microcrystalline cellulose

    hypromellose

    silica colloidal anhydrous

    magnesium stearate.

    Tablet coating:

    hypromellose

    glycerol

    talc

    microcrystalline cellulose

    titanium dioxide (E171)

    red iron oxide (25, 100, 150, 200 and 250 mg strengths only) (E172)

    yellow iron oxide (25, 100 and 200 mg strengths only) (E172)

    black iron oxide (25, 100, 150, 200 and 250 mg strengths only) (E172)

What LUPAXIS tablets looks like and contents of the pack

LUPAXIS 25 mg prolonged-release tablets are light brown, oblong, biconvex film-coated tablets (approximately 5.7 mm x 12,2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet.

LUPAXIS 50 mg prolonged-release tablets are white, oblong, biconvex film-coated tablets (approximately 6.2 mm x 13.2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet.

LUPAXIS 100 mg prolonged-release tablets are light yellow, oblong, biconvex film-coated tablets (approximately 6.7 mm x 14.2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet.

LUPAXIS 150 mg prolonged-release tablets are light pink, oblong, biconvex film-coated tablet (approximately 7.2 mm x 15.2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet.

LUPAXIS 200 mg prolonged-release tablets are yellow, oblong, biconvex film-coated tablets (approximately 7.7 mm x 16.2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet. LUPAXIS 250 mg prolonged-release tablets are reddish brown, oblong, biconvex film-coated tablets (approximately 8.7 mm x 18.2 mm) with score lines on both sides.

The score line is not intended for breaking the tablet. LUPAXIS is available in pack sizes of:

LUPAXIS 25 mg prolonged-release tablets

20, 28, 30, 40, 50, 54, 56, 60 or 100 tablets in child resistant blisters.

LUPAXIS 50 mg,100 mg,150 mg,200 mg,250 mg Prolonged-release Tablets

20, 24, 28, 30, 50, 54, 56, 60 or 100 tablets in child resistant blisters.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Dr. Reddy’s Laboratories (UK) Ltd. 410

Cambridge Science Park, Milton Road, Cambridge, CB4 0PE, United Kingdom

Manufacturer

Develco Pharma GmbH

Grienmatt 27

79650 Schopfheim

Germany

Other formats of this leaflet

A service is available to listen to or request a copy of this leaflet in Braille, large print or audio.

Please call: +44 (0)1748 828873 (UK)

This leaflet was last revised in May 2026

DR00xxxxx

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 08553/0743

Last revision stated in the text: May 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Lupaxis 100 mg prolonged-release tablets

Controlled drug
Yes, Schedule 2 of the Misuse of Drugs Regulations?
  • Controlled drugs are medicines that UK law controls more strictly because they can be misused or cause dependence. The Misuse of Drugs Regulations 2001 divide them into 5 schedules: schedule 1 has the strictest rules, schedule 5 the lightest.
  • Schedule 2 is the strictest group of prescribed medicines, for example strong opioid painkillers and medicines for ADHD.
  • A prescription is valid for 28 days and usually covers up to 30 days of treatment. It cannot be issued as a repeat dispensing prescription.
  • When you collect it, the pharmacist must check whether you are the patient and may ask for ID.
  • Travelling abroad: you can usually carry up to 3 months' supply. Take your prescription or a letter from your doctor to show it is yours, and check the rules of the country you are going to (GOV.UK).
  • Never give it to anyone else.
Active substance Tapentadol
Strength 100 mg
Pharmaceutical form Modified-release tablet
Light yellow, oblong, biconvex film-coated tablet (6.7 mm x 14.2 mm) with score lines on both sides.
The score line is not intended for breaking the tablet.
How is it taken Oral
Excipients Microcrystalline cellulose, Hypromellose, Silica, colloidal anhydrous, Magnesium stearate, Glycerol, Talc, Titanium dioxide (E171), Red iron oxide (E172), Yellow iron oxide (E172), Black iron oxide (E172)
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 4 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Analgesics; opioids; other opioids
  1. N Nervous system drugs
    1. N02 Analgesics
      1. N02A Opioid analgesics
        1. N02AX Other opioids
          1. N02AX06 tapentadol
Marketing authorisation PL 08553/0743 (first authorised 29 March 2023)
Marketing authorisation holder Dr. Reddy’s Laboratories (UK) Ltd.
Codes BNF 04070200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.